GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2010

PerkinElmer and LinaTech to Offer Imaging Solutions for Cancer Treatment

  • PerkinElmer entered into a joint technology development and marketing agreement with LinaTech. The companies will develop, implement, market and distribute imaging technologies for the treatment of various cancers.

    The proposed products will include cost-effective imaging solutions that allow customers to upgrade their legacy film-based radiotherapy systems. They will also incorporate imaging subsystems for sales to radiotherapy system manufacturers.

    “We look forward to very compelling outcomes from our development project, as we seek to create new technologies for the benefit of cancer patients by giving doctors and hospitals more imaging options,” says Brian Giambattista, president, medical imaging, PerkinElmer.

    A first-generation imaging product, the FDA 510k-approved LinaTech TiGRT Image Viewing System, will be showcased at the American Society of Therapeutic Radiology and Oncology in San Diego. It is a Patient Position Verification and Electronic Portal Imaging Device system and is used for patient position verification, patient tumor tracking and localization, portal verification and record, dynamic MLC leaf detection, dosimetry verification, and exist dose recording.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?